Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting
Retrieved on:
Tuesday, November 30, 2021
NSCLC, Oncology, MD Anderson Cancer Center, Assistant professor, Internal medicine, Melanoma, School, Gayle, NKTR, Risk, Nektar, Norris Cotton Cancer Center, Immunotherapy, Division, Congress, Department, Nektar Therapeutics, Head, Tumor microenvironment, University, LSU, Pembrolizumab, Research, American Board of Commissioners for Foreign Missions, Hematology, PROPEL, Failure, Medical school, Louisiana State University, José Felipe Flores, Forward-looking statement, Large-cell lung carcinoma, Lymphocyte, Virology, NASDAQ, ASH, Society, European Society for Medical Oncology, Abstract, Therapy, Ochsner Medical Center, Safety, American Board of Internal Medicine, Lung cancer, Financial toxicity, SAN, Patent, Webcast, Lithium, Pharmaceutical industry
In addition, two clinical data presentations for NKTR-255 in patients with relapsed/refractory hematologic malignancies will be presented during the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia from December 11 to December 14, 2021.
Key Points:
- In addition, two clinical data presentations for NKTR-255 in patients with relapsed/refractory hematologic malignancies will be presented during the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia from December 11 to December 14, 2021.
- ePoster will be on display on the ESMO-IO 2021 virtual meeting platform on Monday, December 6, 2021, at 12:00 pm GMT (7:00 a.m.
- ePoster will be on display on the ASH 2021 virtual meeting platform on Sunday, December 12, 2021, at 6:00 a.m.
- The event will follow the publication of the NKTR-214 (BEMPEG) PROPEL poster (Abstract #140P) on Monday, December 6, 2021.